ERBB2 and breast carcinoma: As lower cost biosimilars of trastuzumab become available [7, 8], breast cancer patients with tumors that overexpress the human epidermal growth factor receptor 2 (HER-2) may find themselves struggling to access a highly effective drug because diagnostic tests that are standard of care for every breast cancer patient in the United States and Europe are unavailable to women in LMIC.